Definium Therapeutics said its DT-120 (lysergide, administered as a 100 µg orally disintegrating tablet) significantly improved major depressive disorder symptoms in a Phase 3 trial, pushing the program closer to potential approval. The company reported a 13.3-point MADRS reduction at six weeks versus 5.2 points with placebo. Definium also said the effect was maintained at 12 weeks, with an 11-point decline from baseline compared with a 3.6-point decline in the placebo arm. The topline results were framed as exceeding analyst expectations and built on earlier momentum for a single-dose approach. The development keeps psychedelics-backed clinical narratives in focus for investors and regulators watching for reproducible efficacy signals in late-stage depression.